Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 28
Encontrada(s) 1 página(s)

Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

An artificial intelligence-based tool for data analysis and prognosis in cancer patients: results from the clarify study

  • Torrente, María
  • Sousa, Pedro A.
  • Hernández, Roberto
  • Blanco, Mariola
  • Calvo de Juan, Virginia
  • Collazo, Ana
  • Guerreiro, Gracinda R.
  • Núñez, Beatriz
  • Pimentao, Joao
  • Sánchez, Juan Cristóbal
  • Campos Yuste, Manuel
  • Costabello, Luca
  • Novacek, Vit
  • Menasalvas, Ernestina
  • Vidal, María Esther
  • Provencio Pulla, Mariano
Artificial intelligence (AI) has contributed substantially in recent years to the resolution of different biomedical problems, including cancer. However, AI tools with significant and widespread impact in oncology remain scarce. The goal of this study is to present an AI-based solution tool for cancer patients data analysis that assists clinicians in identifying the clinical factors associated with poor prognosis, relapse and survival, and to develop a prognostic model that stratifies patients by risk. We used clinical data from 5275 patients diagnosed with non-small cell lung cancer, breast cancer, and non-Hodgkin lymphoma at Hospital Universitario Puerta de Hierro-Majadahonda. Accessible clinical parameters measured with a wearable device and quality of life questionnaires data were also collected. Using an AI-tool, data from 5275 cancer patients were analyzed, integrating clinical data, questionnaires data, and data collected from wearable devices. Descriptive analyses were performed in order to explore the patients’ characteristics, survival probabilities were calculated, and a prognostic model identified low and high-risk profile patients. Conclusion: Overall, the reconstruction of the population’s risk profile for the cancer-specific predictive model was achieved and proved useful in clinical practice using artificial intelligence. It has potential application in clinical settings to improve risk stratification, early detection, and surveillance management of cancer patients, This work was supported by the EU H2020 program, under grant agreement No.875160 (Project CLARIFY) and Centro de Matemática e Aplicações, UID (MAT/00297/2020), Portuguese Foundation of Science and Technology
Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

Multicenter study of the seroprevalence of antibodies against covid-19 in patients with lymphoma: An analysis of the oncological group for the treatment and study of lymphomas (gotel)

  • Franco, Fernando
  • Guirado, María
  • Martínez-Banaclocha, Natividad
  • Gumà, Josep
  • Lavernia, Javier
  • Gómez-Codina, José
  • Rodríguez-Abreu, Delvys
  • Martínez, Fani
  • Barrajón, Enrique
  • Méndez, Miriam
  • Calvo de Juan, Virginia
  • Provencio Pulla, Mariano
The new Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) coronavirus has generated a pandemic, in which there are population groups at higher risk and who are potentially fatal victims of the disease. Cancer patients have been considered a group with special susceptibility, particularly patients with lung tumour involvement and haematological neoplasms. The Spanish Lymphoma Oncology Group (GOTEL) carried out a multicenter study of SARS-CoV-2 seroprevalence in patients with lymphoma. Results: A total of 150 patients were included between 22 May and 11 June 2020. The mean age was 65 years (range 17–89), 70 women (46.5%) and 80 men (53, 5%). At the time of diagnosis of lymphoma, 13 cases were stage I (9%), 27 (18%) stage II, 37 (24.5%) stage III, and 73 (48.5%) stage IV, while 6.6% had a primary extranodal origin. A total of 10 cases with positive serology for SARS-CoV-2 were identified, which is a prevalence of 6% in this population. None of the patients required intensive care unit management and all fully recovered from the infection. Conclusion: IgG antibody seroprevalence in lymphoma patients appears similar to that of the general population and does not show greater aggressiveness, This study was supported by the European Union Horizon 2020 research and innovation programme under grant agreement number 875160
Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Reseña (Review)

Unveiling the Role of the Tumor Microenvironment in the Treatment of Follicular Lymphoma

  • Blanco, Mariola
  • Collazo Lorduy, Ana
  • Yangüas Casás, Natalia
  • Calvo de Juan, Virginia
  • Provencio Pulla, Mariano
Follicular lymphomas (FL) are neoplasms that resemble normal germinal center (GC) B-cells. Normal GC and neoplastic follicles contain non-neoplastic cells such as T-cells, follicular dendritic cells, cancer associated fibroblasts, and macrophages, which define the tumor microenvironment (TME), which itself is an essential factor in tumor cell survival. The main characteristics of the TME in FL are an increased number of follicular regulatory T-cells (Treg) and follicular helper T-cells (Tfh), M2-polarization of macrophages, and the development of a nodular network by stromal cells that creates a suitable niche for tumor growth. All of them play important roles in tumor angiogenesis, inhibition of apoptosis, and immune evasion, which are key factors in tumor progression and transformation risk. Based on these findings, novel therapies have been developed to target specific mutations present in the TME cells, restore immune suppression, and modulate TME., This paper is part of the CLARIFY project, which has received funding from the European Union Horizon 2020 research and innovation program under grant agreement number 875160. NYC is supported by the Fundación Científica Asociación Española Contra el Cáncer (POSTD18029SANC)
Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

Cancer and sars-cov-2 infection: A third-level hospital experience

  • Calvo de Juan, Virginia
  • Fernández Cruz, Ana Elisa
  • Núñez, Beatriz
  • Blanco, Mariola
  • Morito, Ana
  • Martínez, Marta
  • Traseira, Cristina
  • Garitaonaindía, Yago
  • Aguado, Ramón
  • Ramos, Arturo
  • Royuela, Ana
  • Franco, Fernando Fabio
  • Provencio Pulla, Mariano
Introduction: Madrid has been the epicenter of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in Spain. We analyzed our experience with SARS-CoV-2 infected and cancer patients. Patients and Methods: We included patients from March 1 to April 30 2020 at Hospital Universitario Puerta de Hierro, Majadahonda, Madrid (Spain). The inclusion criteria were diagnosis of SARS-CoV-2 infection made by reverse transcription polymerase chain reaction (RT-PCR) of nasopharyngeal specimens in cancer patients who were admitted to the hospital due to the need for respiratory support. The exclusion criteria were suspected cases not confirmed. The primary objective was to analyze the mortality rates of patients with cancer, especially those with lung cancer and COVID-19. Results: Overall in-hospital mortality of cancer patients with coronavirus disease 2019 (COVID-19) was 15.2% similar to 12.7% of the global COVID-19 hospitalized population (p=0.615) and greater than that of patients admitted without SARS-CoV-2 infection during the same period 4.3% (p<0.001). Among 653 patients receiving active cancer therapy during the study period, 24 (3.7%) developed COVID-19 and required admission, 4.2% of those receiving chemotherapy, 9.5% immunotherapy and 2.1% targeted therapies. Lung and breast cancer were the most frequent cancer types (26.1%), followed by colorectal cancer (19.6%). Mortality in patients with lung cancer was 25%. The univariate analysis comparing patients who developed a serious event to those who did not showed that the higher Brescia index, CURB-65 scale, lactate dehydrogenase (LDH) or C-reactive protein (CRP) were the risk factors of developing severe complications. Conclusion: Patients with cancer, especially lung cancer, and SARS-CoV-2 infection have a worse overall prognosis than the general population., This paper is part of a project that has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 875160.
Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

The role of metabolism in tumor immune evasion: Novel approaches to improve immunotherapy

  • Cruz-Bermúdez, Alberto
  • Laza-Briviesca, Raquel
  • Casarrubios, Marta
  • Sierra-Rodero, Belén
  • Provencio Pulla, Mariano
The tumor microenvironment exhibits altered metabolic properties as a consequence of the needs of tumor cells, the natural selection of the most adapted clones, and the selfish relationship with other cell types. Beyond its role in supporting uncontrolled tumor growth, through energy and building materials obtention, metabolism is a key element controlling tumor immune evasion. Immunotherapy has revolutionized the treatment of cancer, being the first line of treatment for multiple types of malignancies. However, many patients either do not benefit from immunotherapy or eventually relapse. In this review we overview the immunoediting process with a focus on the metabolism-related elements that are responsible for increased immune evasion, either through reduced immunogenicity or increased resistance of tumor cells to the apoptotic action of immune cells. Finally, we describe the main molecules to modulate these immune evasion processes through the control of the metabolic microenvironment as well as their clinical developmental status, Work in the authors’ laboratories was supported by “Instituto de Salud Carlos III” (ISCIII) PI19/01652 grant, Ministry of Science and Innovation RTC2017-6502-1 INmunoSIGHT and European Union’s Horizon 2020 research and innovation programme, CLARIFY 875160 grant, to M.P. A.C.-B. received a Spanish Lung Cancer Group (SLCG) grant and is supported by a ISCIII-“Sara Borrell” contract CD19/00170. M.C. is supported by PEJD-2019-PRE/BMD-17006 contract granted to A.C.-B. R.L.-B. was supported by PEJ16/MED/AI-1972 and PEJD-2018-PRE/SAL-8641 from European Social Fund and Comunidad de Madrid, both granted to M.P
Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

Chronodisruption and ambulatory circadian monitoring in cancer patients: beyond the body clock

  • Almaida-Pagan, Pedro F.
  • Torrente, María
  • Campos Yuste, Manuel
  • Provencio Pulla, Mariano
  • Madrid, Juan Antonio
  • Franco Pérez, Fernando Fabio
  • Morilla, Beatriz Rodríguez
  • Cantos, Blanca
  • Sousa, Pedro A.
  • Martínez Madrid, María José
  • Pimentao, Joao
  • Rol, María Ángeles
Circadian rhythms impose daily rhythms a remarkable variety of metabolic and physiological functions, such as cell proliferation, inflammation, and DNA damage response. Accumulating epidemiological and genetic evidence indicates that circadian rhythms’ disruption may be linked to cancer. The integration of circadian biology into cancer research may offer new options for increasing cancer treatment effectiveness and would encompass the prevention, diagnosis, and treatment of this disease. Recent Findings: In recent years, there has been a significant development and use of multi-modal sensors to monitor physical activity, sleep, and circadian rhythms, allowing, for the very first time, scaling accurate sleep monitoring to epidemiological research linking sleep patterns to disease, and wellness applications providing new potential applications. Summary: This review highlights the role of circadian clock in tumorigenesis, cancer hallmarks and introduces the state-of-the-art in sleep-monitoring technologies, discussing the eventual application of insights in clinical settings and cancer research, This work was supported in part by CLARIFY project, within European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No. 875160, Instituto de Fomento de la Región de Murcia (INFO) and the European Regional Development Fund (FEDER)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment

  • Sánchez-Herrero, Estela
  • Serna-Blasco, Roberto
  • Ivanchuk, Vadym
  • García-Campelo, Rosario
  • Dómine Gómez, Manuel
  • Sánchez, José M.
  • Massutí, Bartomeu
  • Reguart, Noemí
  • Camps, Carlos
  • Sanz-Moreno, Sandra
  • Calabuig-Fariñas, Sílvia
  • Jantus-Lewintre, Eloisa
  • Arnal, Magdalena
  • Fernández-Orth, Dietmar
  • Calvo, Virginia
  • González-Rumayor, Víctor
  • Provencio, Mariano
  • Romero, Atocha
Despite impressive and durable responses, nonsmall cell lung cancer (NSCLC) patients treated with anaplastic lymphoma kinase (ALK) inhibitors (ALK-Is) ultimately progress due to development of resistance. Here, we have evaluated the clinical utility of circulating tumor DNA (ctDNA) profiling by next-generation sequencing (NGS) upon disease progression. We collected 26 plasma and two cerebrospinal fluid samples from 24 advanced ALK-positive NSCLC patients at disease progression to an ALK-I. These samples were analyzed by NGS and digital PCR. A tool to retrieve variants at the ALK locus was developed (VALK tool). We identified at least one resistance mutation in the ALK locus in ten (38.5%) plasma samples; the G1269A and G1202R mutations were the most prevalent among patients progressing to first- and second-generation ALK-Is, respectively. Overall, 61 somatic mutations were detected in 14 genes: TP53, ALK, PIK3CA, SMAD4, MAP2K1 (MEK1), FGFR2, FGFR3, BRAF, EGFR, IDH2, MYC, MET, CCND3, and CCND1. Specifically, a deletion in exon 19 in EGFR, a non-V600 BRAF mutation (G466V), and the F129L mutation in MAP2K1 were identified in four patients who showed no objective survival benefit from ALK-Is. Potential ALK-I-resistance mutations were also found in PIK3CA and IDH2. Finally, a c-MYC gain, along with a loss of CCND1 and FGFR3, was detected in a patient progressing on a first-line treatment with crizotinib. We conclude that NGS analysis of liquid biopsies upon disease progression identified different putative ALK-I-resistance mutations in most cases and could be a valuable approach for therapy decision making., The authors wish to thank the donors, and the BIOBANK HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA (HUPHM)/INSTITUTO DE INVESTIGACIÓN SANITARIA PUERTA DE HIERRO-SEGOVIA DE ARANA (IDIPHISA) (PT17/0015/0020 in the Spanish National Biobanks Network) for the human specimens used in this study. This study has been funded by Instituto de Salud Carlos III through the project ‘PI17/01977’ (Co-funded by European Regional Development Fund/European Social Fund ‘A way to make Europe’/‘Investing in your future’). The work presented in this paper also received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 875160. ES was funded by the Consejería de Ciencia, Universidades e Innovación of the Comunidad de Madrid (Doctorados Industriales of the Comunidad de Madrid IND2019/BMD-17258). RS was funded by the Consejería de Educación, Juventud y Deporte of the Comunidad de Madrid and by the Fondo Social Europeo (Programa Operativo de Empleo Juvenil, and Iniciativa de Empleo Juvenil, PEJD-2018-PRE/BMD-8640).
Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

Machine learning estimated probability of relapse in early-stage non-small-cell lung cancer patients with aneuploidy imputation scores and knowledge graph embeddings

  • Buosi, Samuele
  • Timilsina, Mohan
  • Janik, Adrianna
  • Costabello, Luca
  • Torrente, María
  • Provencio Pulla, Mariano
  • Fey, Dirk
  • Novacek, Vit
Low-stage lung cancer is known to recur unpredictably, and patients receiving various treatment methods like radiation, chemotherapy, and immunotherapies have been seen to respond very differently. Identifying a priori if a patient is going to relapse or not could make a difference in terms of saving lives and personalized care offered. In this work, we provide an answer to the following research question: Is it possible to enhance the machine learning (ML) of the estimated probability of relapse in early-stage non-small-cell lung cancer (NSCLC) patients with aneuploidy imputation scores? To predict recurrence in 1,348 early-stage (I–II) NSCLC patients, we train graph ML models utilizing the Spanish pulmonary cancer group knowledge graph enriched with triples from pathway imputation. ML models trained on Knowledge graph data enriched with triples from pathway score imputation present an 82% Precision and 91% Specificity in predicting relapse over 200 patients from a held-out test set. ML models trained using graphs data could prove useful supplemental tool in the TNM classification systems and improve a lung cancer patient's prognosis, This paper is part of the CLARIFY project funded by the EU’s Horizon 2020 Research and Innovation Program (grant No. 875160)
Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Tesis doctoral (DoctoralThesis)

Caracterización de la disfunción sexual asociada al tratamiento oncológico en los pacientes con cáncer de pulmón

  • Ospina Serrano, Aylen Vanessa
Tesis Doctoral inédita leída en la Universidad Autónoma de Madrid, Facultad de Medicina. Departamento de Medicina. Fecha de Lectura: 10-02-2026, Antecedentes: La disfunción sexual puede presentarse como una afección asociada al tratamiento del cáncer. Sin embargo, la información disponible sobre esta alteración es heterogénea y limitada según el tipo de malignidad. Los supervivientes de cáncer de pulmón han aumentado significativamente durante los últimos años debido a los avances terapéuticos. Algunos reportes sugieren que la prevalencia de disfunción sexual podría ser alta en esta población oncológica y esto no ha sido estudiado en profundidad. Metodología: Esta tesis se desarrolló desde noviembre de 2022 hasta junio de 2025 bajo la modalidad de compendio de publicaciones. Dichas publicaciones se basaron en investigaciones realizadas con el objetivo de caracterizar la disfunción sexual asociada al tratamiento oncológico y los factores relacionados con dicha alteración en los pacientes con cáncer de pulmón. Resultados: El primer artículo corresponde a una revisión de la literatura sobre las generalidades de la disfunción sexual en los pacientes con cáncer que sirvió de punto de partida para identificar las características de dicha alteración según el tipo de diagnóstico oncológico y el tratamiento recibido. Con esta revisión, se confirmó que la mayoría de la información procedía de mujeres con cáncer de mama o neoplasias ginecológicas, así como de hombres con cáncer de próstata, y que los datos sobre los pacientes con cáncer de pulmón eran limitados y sugerían que la población femenina se encontraba especialmente afectada. El segundo artículo tuvo como objetivo informar sobre los resultados de un estudio descriptivo sobre las características de la disfunción sexual en una cohorte mixta de 383 pacientes con cáncer de mama, de pulmón o linfoma, procedentes de un hospital local. Como hallazgos relevantes, se confirmó la afectación de las mujeres con cáncer de mama. Adicionalmente, a pesar de que el tamaño de la muestra de los pacientes con cáncer de pulmón (n = 101) era pequeño, se encontró una alta prevalencia de disfunción sexual estadísticamente significativa en el subgrupo de mujeres. El tercer artículo se basó en los resultados de un estudio iberoamericano multicéntrico transversal prospectivo, diseñado para el desarrollo de esta tesis doctoral. Dicha investigación, evaluó las características de la disfunción sexual en una cohorte iberoamericana de 448 pacientes con cáncer de pulmón. Se llevó a cabo en 24 hospitales de España, Colombia, Portugal y Argentina. Entre los resultados, se encontró una alta prevalencia de alteraciones de la salud sexual tanto en hombres como en mujeres después de iniciar el tratamiento oncológico, siendo la población femenina la que presentaba una afectación más frecuente y grave. Además, se evidenció que los factores culturales también estaban relacionados. De forma simultánea a la elaboración de los 3 artículos principales, se generaron 5 comunicaciones que se presentaron en congresos internacionales y que se derivaron de las investigaciones en las que se basó la tesis. Conclusiones: Las publicaciones realizadas durante la tesis doctoral demuestran que la disfunción sexual asociada al tratamiento oncológico es muy frecuente en los pacientes con cáncer de pulmón y que existe una importante disparidad de sexo en la presentación clínica y la gravedad de los síntomas. Estos hallazgos son muy relevantes porque no se tenía plena conciencia de esta situación. Los resultados de este trabajo respaldan la importancia de incluir el cribado y el abordaje de la disfunción sexual en el seguimiento, Ha sido posible gracias a la siguiente financiación: - Parte del proyecto CLARIFY, financiado por el programa de la Unión Europea de Investigación e Innovación Horizonte 2020. (n. 875160) - Estudio LUDICAS financiado y promovido a través del Grupo Español de Cáncer de Pulmón. (GECP), Programa de Doctorado en Medicina y Cirugía
Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

  • Provencio Pulla, Mariano
  • Calvo de Juan, Virginia
  • Domine Gómez, Manuel
Artículo escrito por un elevado número de autores, sólo se referencia el que aparece en primer lugar y los autores pertenecientes a la UAM, The survival of patients with lung cancer has substantially increased in the last decade by about 15%. This increase is, basically, due to targeted therapies available for advanced stages and the emergence of immunotherapy itself. This work aims to study the situation of biomarker testing in Spain. The Thoracic Tumours Registry (TTR) is an observational, prospective, registry-based study that included patients diagnosed with lung cancer and other thoracic tumours, from September 2016 to 2020. This TTR study was sponsored by the Spanish Lung Cancer Group (GECP) Foundation, an independent, scientific, multidisciplinary oncology society that coordinates more than 550 experts and 182 hospitals across the Spanish territory. Nine thousand two hundred thirty-nine patients diagnosed with stage IV non-small cell lung cancer (NSCLC) between 2106 and 2020 were analysed. 7,467 (80.8%) were non-squamous and 1,772 (19.2%) were squamous. Tumour marker testing was performed in 85.0% of patients with non-squamous tumours vs 56.3% in those with squamous tumours (p-value < 0.001). The global testing of EGFR, ALK, and ROS1 was 78.9, 64.7, 35.6% respectively, in non-squamous histology. PDL1 was determined globally in the same period (46.9%), although if we focus on the last 3 years it exceeds 85%. There has been a significant increase in the last few years of all determinations and there are even close to 10% of molecular determinations that do not yet have targeted drug approval but will have it in the near future. 4,115 cases had a positive result (44.5%) for either EGFR, ALK, KRAS, BRAF, ROS1, or high PDL1. Despite the lack of a national project and standard protocol in Spain that regulates the determination of biomarkers, the situation is similar to other European countries. Given the growing number of different determinations and their high positivity, national strategies are urgently needed to implement next-generation sequencing (NGS) in an integrated and cost-effective way in lung cancer, This study was supported by the European Union Horizon 2020 Research and Innovation Program under grant agreement n° 875160 CLARIFY project
Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

Boosting predictive models and augmenting patient data with relevant genomic and pathway information

  • Buosi, Samuele
  • Timilsina, Mohan
  • Torrente, María
  • Provencio Pulla, Mariano
  • Fey, Dirk
  • Novacek, Vit
The recurrence of low-stage lung cancer poses a challenge due to its unpredictable nature and diverse patient responses to treatments. Personalized care and patient outcomes heavily rely on early relapse identification, yet current predictive models, despite their potential, lack comprehensive genetic data. This inadequacy fuels our research focus—integrating specific genetic information, such as pathway scores, into clinical data. Our aim is to refine machine learning models for more precise relapse prediction in early-stage non-small cell lung cancer. To address the scarcity of genetic data, we employ imputation techniques, leveraging publicly available datasets such as The Cancer Genome Atlas (TCGA), integrating pathway scores into our patient cohort from the Cancer Long Survivor Artificial Intelligence Follow-up (CLARIFY) project. Through the integration of imputed pathway scores from the TCGA dataset with clinical data, our approach achieves notable strides in predicting relapse among a held-out test set of 200 patients. By training machine learning models on enriched knowledge graph data, inclusive of triples derived from pathway score imputation, we achieve a promising precision of 82% and specificity of 91%. These outcomes highlight the potential of our models as supplementary tools within tumour, node, and metastasis (TNM) classification systems, offering improved prognostic capabilities for lung cancer patients. In summary, our research underscores the significance of refining machine learning models for relapse prediction in early-stage non-small cell lung cancer. Our approach, centered on imputing pathway scores and integrating them with clinical data, not only enhances predictive performance but also demonstrates the promising role of machine learning in anticipating relapse and ultimately elevating patient outcomes, This work is part of the CLARIFY project funded by the EU’s Horizon2020Research and Innovation Program (grantNo.875160). This research is also co-founded by the Science Foundation Ireland(SFI) under Grant Number SFI/12/RC/2289_P2
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

  • Casarrubios, Marta
  • Provencio, Mariano
  • Nadal, Ernest
  • Insa, Amelia
  • Del Rosario García Campelo, María
  • Lázaro Quintela, Martín
  • Dómine, Manuel
  • Majem, Margarita
  • Rodriguez Abreu, Delvys
  • Martínez Martí, Alex
  • De Castro Carpeño, Javier
  • Cobo, Manuel
  • López Vivanco, Guillermo
  • Del Barco, Edel
  • Bernabé, Reyes
  • Viñolas, Nuria
  • Barneto Aranda, Isidoro
  • Massuti, Bartomeu
  • Sierra Rodero, Belén
  • Martinez Toledo, Cristina
  • Fernández Miranda, Ismael
  • Serna-Blanco, Roberto
  • Romero, Atocha
  • Calvo, Virginia
  • Cruz Bermúdez, Alberto
Background Neoadjuvant chemoimmunotherapy for non-small cell lung cancer (NSCLC) has improved pathological responses and survival rates compared with chemotherapy alone, leading to Food and Drug Administration (FDA) approval of nivolumab plus chemotherapy for resectable stage IB-IIIA NSCLC (AJCC 7th edition) without ALK or EGFR alterations. Unfortunately, a considerable percentage of tumors do not completely respond to therapy, which has been associated with early disease progression. So far, it is impossible to predict these events due to lack of knowledge. In this study, we characterized the gene expression profile of tumor samples to identify new biomarkers and mechanisms behind tumor responses to neoadjuvant chemoimmunotherapy and disease recurrence after surgery. Methods Tumor bulk RNA sequencing was performed in 16 pretreatment and 36 post-treatment tissue samples from 41 patients with resectable stage IIIA NSCLC treated with neoadjuvant chemoimmunotherapy from NADIM trial. A panel targeting 395 genes related to immunological processes was used. Tumors were classified as complete pathological response (CPR) and non-CPR, based on the total absence of viable tumor cells in tumor bed and lymph nodes tested at surgery. Differential-expressed genes between groups and pathway enrichment analysis were assessed using DESeq2 and gene set enrichment analysis. CIBERSORTx was used to estimate the proportions of immune cell subtypes. Results CPR tumors had a stronger pre-established immune infiltrate at baseline than non-CPR, characterized by higher levels of IFNG, GZMB, NKG7, and M1 macrophages, all with a significant area under the receiver operating characteristic curve (ROC) >0.9 for CPR prediction. A greater effect of neoadjuvant therapy was also seen in CPR tumors with a reduction of tumor markers and IFN gamma signaling after treatment. Additionally, the higher expression of several genes, including AKT1, BST2, OAS3, or CD8B; or higher dendritic cells and neutrophils proportions in post-treatment non-CPR samples, were associated with relapse after surgery. Also, high pretreatment PD-L1 and tumor mutational burden levels influenced the post-treatment immune landscape with the downregulation of proliferation markers and type I interferon signaling molecules in surgery samples. Conclusions Our results reinforce the differences between CPR and non-CPR responses, describing possible response and relapse immune mechanisms, opening the possibility of therapy personalization of immunotherapy-based regimens in the neoadjuvant setting of NSCLC.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ALK-Fusion Transcripts Can Be Detected in Extracellular Vesicles (EVs) from Nonsmall Cell Lung Cancer Cell Lines and Patient Plasma: Toward EV-Based Noninvasive Testing

  • Sánchez-Herrero, Estela
  • Campos-Silva, Carmen
  • Cáceres-Martell, Yaiza
  • Robado de Lope, Lucía
  • Sanz-Moreno, Sandra
  • Serna-Blasco, Roberto
  • Rodríguez-Festa, Alejandro
  • Ares Trotta, Dunixe
  • Martín-Acosta, Paloma
  • Patiño, Cristina
  • Coronado, María José
  • Beneítez-Martínez, Alexandra
  • Jara, Ricardo
  • Lago-Baameiro, Nerea
  • Camino, Tamara
  • Cruz-Bermúdez, Alberto
  • Pardo, María
  • González-Rumayor, Víctor
  • Valés-Gómez, Mar
  • Provencio, Mariano
  • Romero, Atocha
[Background]: ALK rearrangements are present in 5% of nonsmall cell lung cancer (NSCLC) tumors and identify patients who can benefit from ALK inhibitors. ALK fusions testing using liquid biopsies, although challenging, can expand the therapeutic options for ALK-positive NSCLC patients considerably. RNA inside extracellular vesicles (EVs) is protected from RNases and other environmental factors, constituting a promising source for noninvasive fusion transcript detection., [Methods]: EVs from H3122 and H2228 cell lines, harboring EML4-ALK variant 1 (E13; A20) and variant 3 (E6a/b; A20), respectively, were successfully isolated by sequential centrifugation of cell culture supernatants. EVs were also isolated from plasma samples of 16 ALK-positive NSCLC patients collected before treatment initiation., [Results]: Purified EVs from cell cultures were characterized by transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and flow cytometry. Western blot and confocal microscopy confirmed the expression of EV-specific markers as well as the expression of EML4-ALK-fusion proteins in EV fractions from H3122 and H2228 cell lines. In addition, RNA from EV fractions derived from cell culture was analyzed by digital PCR (dPCR) and ALK-fusion transcripts were clearly detected. Similarly, plasma-derived EVs were characterized by NTA, flow cytometry, and the ExoView platform, the last showing that EV-specific markers captured EV populations containing ALK-fusion protein. Finally, ALK fusions were identified in 50% (8/16) of plasma EV-enriched fractions by dPCR, confirming the presence of fusion transcripts in EV fractions., [Conclusions]: ALK-fusion transcripts can be detected in EV-enriched fractions. These results set the stage for the development of EV-based noninvasive ALK testing., This study has been funded by Instituto de Salud Carlos III through the project “PI17/01977” (co-funded by European Regional Development Fund/European Social Fund “A way to make Europe”/“Investing in your future”). The work presented in this paper also received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 875160. E. Sánchez-Herrero was funded by the Consejería de Ciencia, Universidades e Innovación of the Comunidad de Madrid (Doctorados Industriales of the Comunidad de Madrid IND2019/BMD-17258). R. Serna-Blasco was funded by the Consejería de Educación, Juventud y Deporte of the Comunidad de Madrid and by the Fondo Social Europeo (Programa Operativo de Empleo Juvenil, and Iniciativa de Empleo Juvenil, PEJD-2018-PRE/BMD-8640). M. Valés-Gómez was funded by Spanish Ministry of Science and Innovation (MCIU/AEI/FEDER, EU) grant RTI2018-093569-B-I00 and Madrid Regional Government under grant “IMMUNOTHERCAN” (S2017/BMD-3733-2). This work was supported by GEIVEX, Network of Excellence in the Research and Innovation on Exosomes REDIEX, SAF2015-71231-REDT, Network of Excellence in Translational NeTwork for the CLinical application of Extracellular VesicleS (TeNTaCLES) (RED2018-102411-T). M. Provencio, grants from BristolMyers Squibb, Roche, and AstraZeneca., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment

  • Sánchez-Herrero, Estela
  • Serna-Blasco, Roberto
  • Ivanchuk, Vadym
  • García-Campelo, Rosario
  • Dómine Gómez, Manuel
  • Sánchez, José M.
  • Massutí, Bartomeu
  • Reguart, Noemí
  • Camps, Carlos
  • Sanz-Moreno, Sandra
  • Calabuig-Fariñas, Sílvia
  • Jantus-Lewintre, Eloisa
  • Arnal, Magdalena
  • Fernández-Orth, Dietmar
  • Calvo, Virginia
  • González-Rumayor, Víctor
  • Provencio, Mariano
  • Romero, Atocha
Despite impressive and durable responses, nonsmall cell lung cancer (NSCLC) patients treated with anaplastic lymphoma kinase (ALK) inhibitors (ALK-Is) ultimately progress due to development of resistance. Here, we have evaluated the clinical utility of circulating tumor DNA (ctDNA) profiling by next-generation sequencing (NGS) upon disease progression. We collected 26 plasma and two cerebrospinal fluid samples from 24 advanced ALK-positive NSCLC patients at disease progression to an ALK-I. These samples were analyzed by NGS and digital PCR. A tool to retrieve variants at the ALK locus was developed (VALK tool). We identified at least one resistance mutation in the ALK locus in ten (38.5%) plasma samples; the G1269A and G1202R mutations were the most prevalent among patients progressing to first- and second-generation ALK-Is, respectively. Overall, 61 somatic mutations were detected in 14 genes: TP53, ALK, PIK3CA, SMAD4, MAP2K1 (MEK1), FGFR2, FGFR3, BRAF, EGFR, IDH2, MYC, MET, CCND3, and CCND1. Specifically, a deletion in exon 19 in EGFR, a non-V600 BRAF mutation (G466V), and the F129L mutation in MAP2K1 were identified in four patients who showed no objective survival benefit from ALK-Is. Potential ALK-I-resistance mutations were also found in PIK3CA and IDH2. Finally, a c-MYC gain, along with a loss of CCND1 and FGFR3, was detected in a patient progressing on a first-line treatment with crizotinib. We conclude that NGS analysis of liquid biopsies upon disease progression identified different putative ALK-I-resistance mutations in most cases and could be a valuable approach for therapy decision making., The authors wish to thank the donors, and the BIOBANK HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA (HUPHM)/INSTITUTO DE INVESTIGACIÓN SANITARIA PUERTA DE HIERRO-SEGOVIA DE ARANA (IDIPHISA) (PT17/0015/0020 in the Spanish National Biobanks Network) for the human specimens used in this study. This study has been funded by Instituto de Salud Carlos III through the project ‘PI17/01977’ (Co-funded by European Regional Development Fund/European Social Fund ‘A way to make Europe’/‘Investing in your future’). The work presented in this paper also received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 875160. ES was funded by the Consejería de Ciencia, Universidades e Innovación of the Comunidad de Madrid (Doctorados Industriales of the Comunidad de Madrid IND2019/BMD-17258). RS was funded by the Consejería de Educación, Juventud y Deporte of the Comunidad de Madrid and by the Fondo Social Europeo (Programa Operativo de Empleo Juvenil, and Iniciativa de Empleo Juvenil, PEJD-2018-PRE/BMD-8640).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

  • Casarrubios, Marta
  • Provencio, Mariano
  • Nadal, Ernest
  • Insa, Amelia
  • Del Rosario García Campelo, María
  • Lázaro Quintela, Martín
  • Dómine, Manuel
  • Majem, Margarita
  • Rodriguez Abreu, Delvys
  • Martínez Martí, Alex
  • De Castro Carpeño, Javier
  • Cobo, Manuel
  • López Vivanco, Guillermo
  • Del Barco, Edel
  • Bernabé, Reyes
  • Viñolas, Nuria
  • Barneto Aranda, Isidoro
  • Massuti, Bartomeu
  • Sierra Rodero, Belén
  • Martinez Toledo, Cristina
  • Fernández Miranda, Ismael
  • Serna-Blanco, Roberto
  • Romero, Atocha
  • Calvo, Virginia
  • Cruz Bermúdez, Alberto
Background Neoadjuvant chemoimmunotherapy for non-small cell lung cancer (NSCLC) has improved pathological responses and survival rates compared with chemotherapy alone, leading to Food and Drug Administration (FDA) approval of nivolumab plus chemotherapy for resectable stage IB-IIIA NSCLC (AJCC 7th edition) without ALK or EGFR alterations. Unfortunately, a considerable percentage of tumors do not completely respond to therapy, which has been associated with early disease progression. So far, it is impossible to predict these events due to lack of knowledge. In this study, we characterized the gene expression profile of tumor samples to identify new biomarkers and mechanisms behind tumor responses to neoadjuvant chemoimmunotherapy and disease recurrence after surgery. Methods Tumor bulk RNA sequencing was performed in 16 pretreatment and 36 post-treatment tissue samples from 41 patients with resectable stage IIIA NSCLC treated with neoadjuvant chemoimmunotherapy from NADIM trial. A panel targeting 395 genes related to immunological processes was used. Tumors were classified as complete pathological response (CPR) and non-CPR, based on the total absence of viable tumor cells in tumor bed and lymph nodes tested at surgery. Differential-expressed genes between groups and pathway enrichment analysis were assessed using DESeq2 and gene set enrichment analysis. CIBERSORTx was used to estimate the proportions of immune cell subtypes. Results CPR tumors had a stronger pre-established immune infiltrate at baseline than non-CPR, characterized by higher levels of IFNG, GZMB, NKG7, and M1 macrophages, all with a significant area under the receiver operating characteristic curve (ROC) >0.9 for CPR prediction. A greater effect of neoadjuvant therapy was also seen in CPR tumors with a reduction of tumor markers and IFN gamma signaling after treatment. Additionally, the higher expression of several genes, including AKT1, BST2, OAS3, or CD8B; or higher dendritic cells and neutrophils proportions in post-treatment non-CPR samples, were associated with relapse after surgery. Also, high pretreatment PD-L1 and tumor mutational burden levels influenced the post-treatment immune landscape with the downregulation of proliferation markers and type I interferon signaling molecules in surgery samples. Conclusions Our results reinforce the differences between CPR and non-CPR responses, describing possible response and relapse immune mechanisms, opening the possibility of therapy personalization of immunotherapy-based regimens in the neoadjuvant setting of NSCLC.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

  • Robado de Lope, Lucía
  • Serna-Blasco, Roberto
  • Diz Tain, Pilar
  • provencio, mariano
  • Nadal, Ernest
  • Massuti, Bartomeu
  • MARTINEZ-MARTI, ALEX
BRAF; Immunotherapy; NSCLC, BRAF; Immunoteràpia; NSCLC, BRAF; Inmunoterapia; NSCLC, Background Immunotherapy-based treatments have demonstrated high efficacy in patients with advanced and locally advanced non-small-cell lung cancer (NSCLC). BRAF mutations affect a small but significant fraction of NSCLC. The efficacy of these therapies in this subgroup of patients is unknown. Materials and methods Plasma and tissue samples from 116 resectable stage IIIA/B NSCLC patients, included in NADIM and NADIM II clinical trials (NADIM cohort), and from a prospective academic cohort with 84 stage IV NSCLC patients (BLI-O cohort), were analyzed by next-generation sequencing. Results The p.G464E, p.G466R, p.G466V, p.G469V, p.L597Q, p.T599I, p.V600E (n = 2) BRAF mutations, were identified in four (3.45 %) samples from the NADIM cohort, all of which were cases treated with neoadjuvant chemoimmunotherapy (CH-IO), and four (4.76 %) samples from the BLI-O cohort, corresponding to cases treated with first-line immunotherapy (n = 2) or CH-IO (n = 2). All these patients were alive and had no evidence of disease at data cut-off. Conversely, patients with BRAF wild-type (wt) tumors in the BLI-O cohort had a median progression-free survival (PFS) of 5.49 months and a median overall survival (OS) of 12.00 months (P-LogRank = 0.013 and 0.046, respectively). Likewise, PFS and OS probabilities at 36 months were 60.5 % and 76.1 % for patients with BRAF-wt tumors in the NADIM cohort. The pathological complete response (pCR) rate after neoadjuvant CH-IO in patients with BRAF-positive tumors (n = 4) was 100 %, whereas the pCR rate in the BRAF-wt population was 44.3 % (RR: 2.26; 95 % CI: 1.78–2.85; P < 0.001). Conclusion BRAF mutations may be a good prognostic factor for advanced and locally advanced NSCLC patients undergoing immunotherapy-based treatments., This study was funded by Bristol-Myers Squibb. The study was also supported by the European Union Horizon 2020 Research and Innovation program (European Commission) under grant agreement no. 875160. In addition, the project received funds from Instituto de Salud Carlos III (ISCIII) PI19/01652, PI21/01500 (Co-funded by European Regional Development Fund/ European Social Fund ‘A way to make Europe’/‘Investing in your future’ from European Commission) and grant RTC2019-007359–1 (BLI- O) from the Ministry of Science and Innovation. A.C-B. is supported by Sara Borrell fellowship grant n°CD19/00170. Instituto de Salud Carlos III (ISCIII). L R dL is supported by grant JDC2022-049091-I The Spanish State Research Agency.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non–Small Cell Lung Cancer

  • Provencio Pulla, Mariano
  • Serna-Blasco, Roberto
  • Nadal, Ernest
  • González Larriba, Jose Luis
  • MARTINEZ-MARTI, ALEX
  • Bernabé, Reyes
Prognostic stratification; Resectable non-small cell lung cancer, Estratificación pronóstica; Cáncer de pulmón de células no pequeñas resecable, Estratificació pronòstica; Càncer de pulmó de cèl·lules no petites resecable, Purpose: Perioperative chemoimmunotherapy is the standard of care for resectable, locally advanced non–small cell lung cancer (NSCLC). Although pathologic complete response (pCR) correlates with excellent survival outcomes, some patients without pCR still exhibit long-term survival. In this study, we evaluate the added value of minimal residual disease (MRD). Experimental Design: MRD was assessed in 60 patients from the NADIM II trial (NCT03838159) using the Guardant Reveal assay. In NADIM II, patients with NSCLC without EGFR or ALK alterations were randomly assigned to receive neoadjuvant nivolumab plus chemotherapy (experimental arm) or chemotherapy alone, followed by surgery. Patients in the experimental arm with R0 resection received adjuvant nivolumab. Results: The MRD detection rate was 9.6%. MRD after surgery or during adjuvant treatment was associated with inferior event-free survival (EFS) and overall survival [OS; hazard ratio (HR): 10.2; 95% confidence interval (CI), 3.7–28.3 and HR: 10.0; 95% CI, 2.0–49.9, respectively]. All patients with MRD-negative plasma samples in at least two time points were alive [HR: not estimable (NE), P < 0.001], with only one relapse (HR: 41.6; 95% CI, 5.0–348.8), corresponding to a patient relapsing with a single brain metastasis. MRD enhanced the prognostic value of pCR for both EFS (P < 0.001) and OS (P = 0.015). Among non-pCR patients, MRD remained a significant prognostic marker (HR: 6.2; 95% CI, 2.2–17.1 and HR: 6.5; 95% CI, 1.3–32.5, for EFS and OS respectively). All non-pCR patients with MRD-negative results in at least two time points were alive (HR: NE, P = 0.025), with one relapse (HR: 19.9; 95% CI, 2.4–165.6), corresponding to the aforementioned case. Conclusions: MRD may refine prognostic evaluation beyond pCR in resectable NSCLC undergoing perioperative chemoimmunotherapy., We thank the patients and their caregivers; the research teams, data managers, and nurses at each participating center; and the personnel of the Spanish Lung Cancer Group. The NADIM II trial was sponsored by the Spanish Lung Cancer Group (www.gecp.org). The funders had no role in the conduct of the study; the collection, management, analysis, or interpretation of the data; the preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. The NADIM II trial was funded by Bristol Myers Squibb. The molecular analyses presented here were supported by grants PI21/01500, PI22/01223, and PI24/01725 from the Instituto de Salud Carlos III (ISCIII), co-funded by the European Regional Development Fund and the European Social Fund (“A way to make Europe”/“Investing in your future”), and by grant CPP2022-009545 (STRAGEN-IO) from the Plan Estatal de Investigación Científica, Técnica y de Innovación 2021 to 2023 and the Plan de Recuperación, Transformación y Resiliencia (NextGenerationEU/PRTR; Agencia Estatal de Investigación). The project also received funding from the European Union’s Horizon 2020 Research and Innovation Program (European Commission) under grant agreement no. 875160. P. Mediavilla-Medel was supported by the ISCIII fellowship FI22/00321. Additional support was received from Guardant Health, Inc.
Archivo Digital UPM
Publicación Artículo científico (JournalArticle)

Transformers for extracting breast cancer information from Spanish clinical narratives

  • Solarte Pabón, Oswaldo|||0000-0003-0315-2838
  • Montenegro, Orlando
  • García Barragán, Álvaro
  • Torrente Regidor, María
  • Provencio Pulla, Mariano
  • Menasalvas Ruiz, Ernestina|||0000-0002-5615-6798
  • Robles Forcada, Víctor|||0000-0003-3937-2269
Archivo Digital UPM
Publicación Artículo científico (JournalArticle)

PALADIN: a process-based constraint language for data validation

  • Díaz Honrubia, Antonio Jesús|||0000-0001-5464-0714
  • Rohde, Philipp D.|||0000-0002-9835-4354
  • Niazmand, Emetis|||0000-0001-8194-8079
  • Menasalvas Ruiz, Ernestina|||0000-0002-5615-6798
  • Vidal, María Esther
Archivo Digital UPM
Publicación Artículo científico (JournalArticle)

GPT for medical entity recognition in Spanish

  • García Barragán, Álvaro|||0009-0007-6377-8150
  • González Calatayud, Alberto|||0009-0006-6439-4581
  • Solarte Pabón, Oswaldo|||0000-0003-0315-2838
  • Provencio Pulla, Mariano|||0000-0001-6315-7919
  • Menasalvas Ruiz, Ernestina|||0000-0002-5615-6798
  • Robles Forcada, Víctor|||0000-0003-3937-2269
Archivo Digital UPM
Publicación Artículo científico (JournalArticle)

Knowledge graphs for enhancing transparency in health data ecosystems

  • Aisopos, Fotis|||0000-0002-3942-0673
  • Jozashoori, Samaneh|||0000-0003-1702-8707
  • Niazmand, Emetis|||0000-0001-8194-8079
  • Purohit, Disha|||0000-0002-1442-335X
  • Rivas Méndez, Ariam|||0000-0003-4916-5220
  • Sakor, Ahmad|||0000-0001-8007-7021
  • Iglesias, Enrique
  • Vogiatzis, Dimitrios
  • Menasalvas Ruiz, Ernestina|||0000-0002-5615-6798
  • Rodríguez González, Alejandro|||0000-0001-8801-4762
  • Vigueras González, Guillermo Antonio|||0000-0003-0162-5267
  • Gomez-Bravo Puerta, Daniel
  • Torrente Regidor, María|||0000-0001-8791-7660
  • Hernández López, Roberto|||0000-0003-2756-4829
  • Provencio Pulla, Mariano|||0000-0001-6315-7919
  • Dalianis, Athanasios|||0000-0003-2629-2964
  • Triantafillou, Anna
  • Paliouras, Georgios
  • Vidal, María Esther|||0000-0003-1160-8727
Archivo Digital UPM
Publicación Artículo científico (JournalArticle)

NSSC: a neuro-symbolic AI system for enhancing accuracy of named entity recognition and linking from oncologic clinical notes

  • García Barragán, Álvaro|||0009-0007-6377-8150
  • Sakor, Ahmad|||0000-0001-8007-7021
  • Vidal, María Esther|||0000-0003-1160-8727
  • Menasalvas Ruiz, Ernestina|||0000-0002-5615-6798
  • Sánchez González, Juan Cristóbal|||0000-0001-6442-1574
  • Provencio, Mariano|||0000-0001-6315-7919
  • Robles Forcada, Víctor|||0000-0003-3937-2269
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy

  • Casarrubios, Marta|||0000-0002-2872-9552
  • Cruz-Bermúdez, Alberto|||0000-0001-5136-7011
  • Nadal, Ernest|||0000-0002-9674-5554
  • Insa, Amelia|||0000-0002-3438-6170
  • García Campelo, María del Rosario
  • Lázaro, Martín|||0000-0002-0657-4713
  • Dómine Gómez, Manuel|||0000-0003-1634-9832
  • Majem Tarruella, Margarita|||0000-0002-9919-7485
  • Rodríguez-Abreu, Delvys|||0000-0003-0506-1366
  • Martinez-Marti, Alex|||0000-0002-6714-9526
  • Castro, Javier de|||0000-0002-3622-6306
  • Cobo, Manuel|||0000-0003-3402-1144
  • López-Vivanco, Guillermo|||0000-0003-3800-6224
  • Del Barco Morillo, Edel|||0000-0001-6443-0585
  • Bernabé, Reyes|||0000-0003-0312-9195
  • Viñolas, Nuria|||0000-0002-8287-2739
  • Barneto Aranda, Isidoro|||0000-0001-6302-1034
  • Viteri, Santiago|||0000-0002-7572-1123
  • Massuti, Bartomeu|||0000-0002-6247-4493
  • Barquín, Miguel
  • Laza-Briviesca, Raquel
  • Sierra Rodero, Belén|||0000-0003-0276-6088
  • Parra, Edwin R.|||0000-0001-9068-1636
  • Sanchez-Espiridion, Beatriz
  • Rocha, Pedro
  • Kadara, Humam
  • Wistuba, Ignacio I.
  • Romero, Atocha|||0000-0002-1634-7397
  • Calvo, Virginia|||0000-0002-3503-4847
  • Provencio Pulla, Mariano|||0000-0001-6315-7919
Purpose: Characterization of the T-cell receptor (TCR) repertoire may be a promising source for predictive biomarkers of pathologic response to immunotherapy in locally advanced non-small cell lung cancer (NSCLC). Experimental Design: In this study, next-generation TCR sequencing was performed in peripheral blood and tissue samples of 40 patients with NSCLC, before and after neoadjuvant chemoimmunotherapy (NADIM clinical trial, NCT03081689), considering their complete pathologic response (CPR) or non-CPR. Beyond TCR metrics, tissue clones were ranked by their frequency and spatiotemporal evolution of top 1% clones was determined. Results: We have found a positive association between an uneven TCR repertoire in tissue samples at diagnosis and CPR at surgery. Moreover, TCR most frequently ranked clones (top 1%) present in diagnostic biopsies occupied greater frequency in the total clonal space of CPR patients, achieving an AUC ROC to identify CPR patients of 0.967 (95% confidence interval, 0.897-1.000; P ¼ 0.001), and improving the results of PD-L1 tumor proportion score (TPS; AUC = 0.767; P = 0.026) or tumor mutational burden (TMB; AUC = 0.550; P = 0.687). Furthermore, tumors with high pretreatment top 1% clonal space showed similar immune cell populations but a higher immune reactive gene expression profile. Finally, the selective expansion of pretreatment tissue top 1% clones in peripheral blood of CPR patients suggests also a peripheral immunosurveillance, which could explain the high survival rate of these patients. Conclusions: We have identified two parameters derived from TCR repertoire analysis that could outperform PD-L1 TPS and TMB as predictive biomarkers of CPR after neoadjuvant chemoimmunotherapy, and unraveled possible mechanisms of CPR involving enhanced tumor immunogenicity and peripheral immunosurveillance.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial

  • Sierra Rodero, Belén|||0000-0003-0276-6088
  • Cruz-Bermúdez, Alberto|||0000-0001-5136-7011
  • Nadal, Ernest|||0000-0002-9674-5554
  • Garitaonaindiá, Yago
  • Insa, Amelia|||0000-0002-3438-6170
  • Mosquera, Joaquín
  • Casal-Rubio, Joaquín
  • Dómine Gómez, Manuel|||0000-0003-1634-9832
  • Majem Tarruella, Margarita|||0000-0002-9919-7485
  • Rodríguez-Abreu, Delvys|||0000-0003-0506-1366
  • Martinez-Marti, Alex|||0000-0002-6714-9526
  • Castro, Javier de|||0000-0002-3622-6306
  • Cobo, Manuel|||0000-0003-3402-1144
  • López Vivanco, Guillermo
  • Del Barco Morillo, Edel|||0000-0001-6443-0585
  • Bernabé, Reyes|||0000-0003-0312-9195
  • Viñolas, Nuria|||0000-0002-8287-2739
  • Barneto Aranda, Isidoro|||0000-0001-6302-1034
  • Viteri, Santiago|||0000-0002-7572-1123
  • Massuti, Bartomeu|||0000-0002-6247-4493
  • Laza-Briviesca, Raquel
  • Casarrubios, Marta|||0000-0002-2872-9552
  • Garciá-Grande, Aránzazu
  • Romero, Atocha|||0000-0002-1634-7397
  • Franco, Fernando|||0000-0001-8964-5136
  • Provencio Pulla, Mariano|||0000-0001-6315-7919
Background Pneumonitis (Pn) is one of the main immune-related adverse effects, having a special importance in lung cancer, since they share affected tissue. Despite its clinical relevance, Pn development remains an unpredictable treatment adverse effect, whose mechanisms are mainly unknown, being even more obscure when it is associated to chemoimmunotherapy. Methods In order to identify parameters associated to treatment related Pn, we analyzed clinical variables and molecular parameters from 46 patients with potentially resectable stage IIIA non-small-cell lung cancer treated with neoadjuvant chemoimmunotherapy included in the NADIM clinical trial (NCT03081689). Pn was defined as clinical or radiographic evidence of lung inflammation without alternative diagnoses, from treatment initiation to 180 days. Results Among 46 patients, 12 developed Pn (26.1%). Sex, age, smoking status, packs-year, histological subtype, clinical or pathological response, progression-free survival, overall survival and number of nivolumab cycles, were not associated to Pn development. Regarding molecular parameters at diagnosis, Pn development was not associated to programmed death ligand 1, TPS, T cell receptor repertoire parameters, or tumor mutational burden. However, patients who developed Pn had statistically significant lower blood median levels of platelet to monocyte ratio (p=0.012) and teratocarcinoma-derived growth factor 1 (p=0.013; area under the curve (AUC) 0.801), but higher median percentages of natural killers (NKs) (p=0.019; AUC 0.786), monocytes (p=0.017; AUC 0.791), MSP (p=0.006; AUC 0.838), PARN (p=0.017; AUC 0.790), and E-Cadherin (p=0.022; AUC 0.788). In addition, the immune scenario of Pn after neoadjuvant treatment involves: high levels of neutrophils and NK cells, but low levels of B and T cells in peripheral blood; increased clonality of intratumoral T cells; and elevated plasma levels of several growth factors (EGF, HGF, VEGF, ANG-1, PDGF, NGF, and NT4) and inflammatory cytokines (MIF, CCL16, neutrophil gelatinase-associated lipocalin, BMP-4, and u-PAR). Conclusions Although statistically underpowered, our results shed light on the possible mechanisms behind Pn development, involving innate and adaptative immunity, and open the possibility to predict patients at high risk. If confirmed, this may allow the personalization of both, the surveillance strategy and the therapeutic approaches to manage Pn in patients receiving chemoimmunotherapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

  • Casarrubios, Marta|||0000-0002-2872-9552
  • Provencio Pulla, Mariano|||0000-0001-6315-7919
  • Nadal, Ernest|||0000-0002-9674-5554
  • Insa, Amelia|||0000-0002-3438-6170
  • Del Rosario García-Campelo, María|||0000-0003-2113-1504
  • Lázaro, Martín|||0000-0002-0657-4713
  • Dómine Gómez, Manuel|||0000-0003-1634-9832
  • Majem Tarruella, Margarita|||0000-0002-9919-7485
  • Rodríguez-Abreu, Delvys|||0000-0003-0506-1366
  • Martinez-Marti, Alex|||0000-0002-6714-9526
  • Castro, Javier de|||0000-0002-3622-6306
  • Cobo, Manuel|||0000-0003-3402-1144
  • López-Vivanco, Guillermo|||0000-0003-3800-6224
  • Del Barco Morillo, Edel|||0000-0001-6443-0585
  • Bernabé, Reyes|||0000-0003-0312-9195
  • Viñolas, Nuria|||0000-0002-8287-2739
  • Barneto Aranda, Isidoro|||0000-0001-6302-1034
  • Massuti, Bartomeu|||0000-0002-6247-4493
  • Sierra Rodero, Belén|||0000-0003-0276-6088
  • Martinez-Toledo, Cristina|||0000-0002-0663-0674
  • Fernández-Miranda, Ismael|||0000-0002-5136-7270
  • Serna-Blanco, Roberto|||0000-0002-7563-9613
  • Romero, Atocha|||0000-0002-1634-7397
  • Calvo, Virginia|||0000-0002-3503-4847
  • Cruz-Bermúdez, Alberto|||0000-0001-5136-7011
Background Neoadjuvant chemoimmunotherapy for non-small cell lung cancer (NSCLC) has improved pathological responses and survival rates compared with chemotherapy alone, leading to Food and Drug Administration (FDA) approval of nivolumab plus chemotherapy for resectable stage IB-IIIA NSCLC (AJCC 7th edition) without ALK or EGFR alterations. Unfortunately, a considerable percentage of tumors do not completely respond to therapy, which has been associated with early disease progression. So far, it is impossible to predict these events due to lack of knowledge. In this study, we characterized the gene expression profile of tumor samples to identify new biomarkers and mechanisms behind tumor responses to neoadjuvant chemoimmunotherapy and disease recurrence after surgery. Methods Tumor bulk RNA sequencing was performed in 16 pretreatment and 36 post-treatment tissue samples from 41 patients with resectable stage IIIA NSCLC treated with neoadjuvant chemoimmunotherapy from NADIM trial. A panel targeting 395 genes related to immunological processes was used. Tumors were classified as complete pathological response (CPR) and non-CPR, based on the total absence of viable tumor cells in tumor bed and lymph nodes tested at surgery. Differential-expressed genes between groups and pathway enrichment analysis were assessed using DESeq2 and gene set enrichment analysis. CIBERSORTx was used to estimate the proportions of immune cell subtypes. Results CPR tumors had a stronger pre-established immune infiltrate at baseline than non-CPR, characterized by higher levels of IFNG, GZMB, NKG7, and M1 macrophages, all with a significant area under the receiver operating characteristic curve (ROC).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Minimal Residual Disease Enhances Prognostic Stratification beyond Pathologic Response in Resectable Non–Small Cell Lung Cancer

  • Provencio Pulla, Mariano
  • Serna-Blasco, Roberto
  • Nadal, Ernest
  • González Larriba, Jose Luis
  • MARTINEZ-MARTI, ALEX
  • Bernabé, Reyes
Prognostic stratification; Resectable non-small cell lung cancer, Estratificación pronóstica; Cáncer de pulmón de células no pequeñas resecable, Estratificació pronòstica; Càncer de pulmó de cèl·lules no petites resecable, Purpose: Perioperative chemoimmunotherapy is the standard of care for resectable, locally advanced non–small cell lung cancer (NSCLC). Although pathologic complete response (pCR) correlates with excellent survival outcomes, some patients without pCR still exhibit long-term survival. In this study, we evaluate the added value of minimal residual disease (MRD). Experimental Design: MRD was assessed in 60 patients from the NADIM II trial (NCT03838159) using the Guardant Reveal assay. In NADIM II, patients with NSCLC without EGFR or ALK alterations were randomly assigned to receive neoadjuvant nivolumab plus chemotherapy (experimental arm) or chemotherapy alone, followed by surgery. Patients in the experimental arm with R0 resection received adjuvant nivolumab. Results: The MRD detection rate was 9.6%. MRD after surgery or during adjuvant treatment was associated with inferior event-free survival (EFS) and overall survival [OS; hazard ratio (HR): 10.2; 95% confidence interval (CI), 3.7–28.3 and HR: 10.0; 95% CI, 2.0–49.9, respectively]. All patients with MRD-negative plasma samples in at least two time points were alive [HR: not estimable (NE), P < 0.001], with only one relapse (HR: 41.6; 95% CI, 5.0–348.8), corresponding to a patient relapsing with a single brain metastasis. MRD enhanced the prognostic value of pCR for both EFS (P < 0.001) and OS (P = 0.015). Among non-pCR patients, MRD remained a significant prognostic marker (HR: 6.2; 95% CI, 2.2–17.1 and HR: 6.5; 95% CI, 1.3–32.5, for EFS and OS respectively). All non-pCR patients with MRD-negative results in at least two time points were alive (HR: NE, P = 0.025), with one relapse (HR: 19.9; 95% CI, 2.4–165.6), corresponding to the aforementioned case. Conclusions: MRD may refine prognostic evaluation beyond pCR in resectable NSCLC undergoing perioperative chemoimmunotherapy., We thank the patients and their caregivers; the research teams, data managers, and nurses at each participating center; and the personnel of the Spanish Lung Cancer Group. The NADIM II trial was sponsored by the Spanish Lung Cancer Group (www.gecp.org). The funders had no role in the conduct of the study; the collection, management, analysis, or interpretation of the data; the preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. The NADIM II trial was funded by Bristol Myers Squibb. The molecular analyses presented here were supported by grants PI21/01500, PI22/01223, and PI24/01725 from the Instituto de Salud Carlos III (ISCIII), co-funded by the European Regional Development Fund and the European Social Fund (“A way to make Europe”/“Investing in your future”), and by grant CPP2022-009545 (STRAGEN-IO) from the Plan Estatal de Investigación Científica, Técnica y de Innovación 2021 to 2023 and the Plan de Recuperación, Transformación y Resiliencia (NextGenerationEU/PRTR; Agencia Estatal de Investigación). The project also received funding from the European Union’s Horizon 2020 Research and Innovation Program (European Commission) under grant agreement no. 875160. P. Mediavilla-Medel was supported by the ISCIII fellowship FI22/00321. Additional support was received from Guardant Health, Inc.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC

  • Robado de Lope, Lucía
  • Serna-Blasco, Roberto
  • Diz Tain, Pilar
  • provencio, mariano
  • Nadal, Ernest
  • Massuti, Bartomeu
  • MARTINEZ-MARTI, ALEX
BRAF; Immunotherapy; NSCLC, BRAF; Immunoteràpia; NSCLC, BRAF; Inmunoterapia; NSCLC, Background Immunotherapy-based treatments have demonstrated high efficacy in patients with advanced and locally advanced non-small-cell lung cancer (NSCLC). BRAF mutations affect a small but significant fraction of NSCLC. The efficacy of these therapies in this subgroup of patients is unknown. Materials and methods Plasma and tissue samples from 116 resectable stage IIIA/B NSCLC patients, included in NADIM and NADIM II clinical trials (NADIM cohort), and from a prospective academic cohort with 84 stage IV NSCLC patients (BLI-O cohort), were analyzed by next-generation sequencing. Results The p.G464E, p.G466R, p.G466V, p.G469V, p.L597Q, p.T599I, p.V600E (n = 2) BRAF mutations, were identified in four (3.45 %) samples from the NADIM cohort, all of which were cases treated with neoadjuvant chemoimmunotherapy (CH-IO), and four (4.76 %) samples from the BLI-O cohort, corresponding to cases treated with first-line immunotherapy (n = 2) or CH-IO (n = 2). All these patients were alive and had no evidence of disease at data cut-off. Conversely, patients with BRAF wild-type (wt) tumors in the BLI-O cohort had a median progression-free survival (PFS) of 5.49 months and a median overall survival (OS) of 12.00 months (P-LogRank = 0.013 and 0.046, respectively). Likewise, PFS and OS probabilities at 36 months were 60.5 % and 76.1 % for patients with BRAF-wt tumors in the NADIM cohort. The pathological complete response (pCR) rate after neoadjuvant CH-IO in patients with BRAF-positive tumors (n = 4) was 100 %, whereas the pCR rate in the BRAF-wt population was 44.3 % (RR: 2.26; 95 % CI: 1.78–2.85; P < 0.001). Conclusion BRAF mutations may be a good prognostic factor for advanced and locally advanced NSCLC patients undergoing immunotherapy-based treatments., This study was funded by Bristol-Myers Squibb. The study was also supported by the European Union Horizon 2020 Research and Innovation program (European Commission) under grant agreement no. 875160. In addition, the project received funds from Instituto de Salud Carlos III (ISCIII) PI19/01652, PI21/01500 (Co-funded by European Regional Development Fund/ European Social Fund ‘A way to make Europe’/‘Investing in your future’ from European Commission) and grant RTC2019-007359–1 (BLI- O) from the Ministry of Science and Innovation. A.C-B. is supported by Sara Borrell fellowship grant n°CD19/00170. Instituto de Salud Carlos III (ISCIII). L R dL is supported by grant JDC2022-049091-I The Spanish State Research Agency.